PEYONA SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CAFFEINE CITRATE

可用日期:

CHIESI FARMACEUTICI S.P.A.

ATC代码:

N06BC01

INN（国际名称）:

CAFFEINE

剂量:

20MG

药物剂型:

SOLUTION

组成:

CAFFEINE CITRATE 20MG

给药途径:

INTRAVENOUS

每包单位数:

15G/50G

处方类型:

Prescription Recommended

治疗领域:

Respiratory and CNS Stimulants

產品總結:

Active ingredient group (AIG) number: 0162054001; AHFS:

授权状态:

APPROVED

授权日期:

2020-03-04

产品特点

_Product Monograph- Peyona_
_TM_
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PEYONA
TM
CAFFEINE CITRATE INJECTION AND CAFFEINE CITRATE ORAL SOLUTION
MFR. STD.
20 MG / ML SOLUTION, INTRAVENOUS / ORAL
(EACH ML CONTAINS 20 MG CAFFEINE CITRATE, EQUIVALENT TO 10 MG CAFFEINE
BASE)
PSYCHOANALEPTICS, XANTHINE DERIVATIVES ATC CODE: N06BC01
SPONSOR :
Chiesi Farmaceutici SpA
Via Palermo 26/A
43122 Parma
Italy
DATE OF INITIAL CREATION:
March 3, 2020
IMPORTED BY:
Methapharm Inc
81 Sinclair Boulevard
Brantford, ON N3S 7X6
Canada
Submission Control No: 225810
_ _
_Product Monograph- Peyona_
_TM_
_ _
_Page 2 of 25 _
TABLE OF CONTENTS
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
Pediatrics
..............................................................................................................................4
Geriatrics
..............................................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................................................5
4
DOSAGE AND ADMINISTRATION
.............................................................................5
Dosing Considerations
.........................................................................................................5
Recommended Dose and Dosage Adjustment
.....................................................................5
Administration
.....................................................................................................................7
5
OVERDOSAGE
...........................................